Penpulimab with RMA for newly diagnosed brain lymphoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of drugs for people newly diagnosed with primary central nervous system lymphoma (a rare type of brain lymphoma). The treatment aims to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with primary central nervous system lymphoma confirmed by biopsy.
- An MRI within the past 28 days must show at least one measurable tumor, or you have abnormal spinal fluid or eye involvement.
- Your performance status (ability to care for yourself) can range from fully active to bedridden (ECOG 0-4).
- The lymphoma must be only in the brain, spinal cord, or eyes, not in other organs or lymph nodes.
- You must not have had previous treatment with certain immunotherapy drugs (like anti-PD-1 or CAR T cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial studies a treatment plan for people with newly diagnosed non-Hodgkin lymphoma that has spread to the brain and covering tissues (meninges). It combines medicines given through the bloodstream with immunotherapy placed into the fluid around the brain (CSF) to improve control of the lymphoma.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.